Author + information
- S. Cay,
- O. Ozeke,
- F. Ozcan,
- D. Aras and
- S. Topaloglu
The aim of the current study was to compare the new oral anticoagulants with warfarin in patients with atrial fibrillation and diabetes.
Four large randomized trials of the new oral anticoagulants (n = 18086) were included in this meta-analysis (Apixaban 5 mg, Rivaroxaban 20 mg, Dabigatran 150 mg, and Edoxaban 60 mg). Subgroup analysis of diabetic patients with atrial fibrillation was performed.
In patients with atrial fibrillation and diabetes, there was a statistically significant reduction in the primary outcome of stroke or systemic embolism with the new oral anticoagulants (RR = 0.80 [95% CI (0.66 - 0.96)], p = 0.019) compared to warfarin by the fixed effect model (Figure 1). The P value for Egger’s test is 0.57. Therefore no apparent bias exists in the studies included in the meta-analysis (Figure 2).
The new oral anticoagulants were effective in reducing stroke or systemic embolism in patients with atrial fibrillation and diabetes.